Hematologic Malignancy: Clinical Trials

18 trials for Hematologic Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 recruiting. 18 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Recruiting 18
Phase 26Recruiting 6

Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy
Efineptakin Alfa (rhIL-7-hyFc) - Hematologic Malignancy
Phase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute122026-12-012026-11-17
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
Phase 1RecruitingSt. Jude Children's Research Hospital702026-10-032026-08-28
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.
Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor
Phase 1 / Phase 2RecruitingChinese PLA General Hospital242026-06-052026-06-08
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT
Phase 1 / Phase 2RecruitingRuijin Hospital302026-06-012026-06-23
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy
Phase 1RecruitingSt. Jude Children's Research Hospital302025-09-252026-06-02
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
G-CSF, Decitabine, Venetoclax - Myeloid Malignancy, Hematologic Malignancy
Phase 1RecruitingUniversity of Alabama at Birmingham202025-07-172026-03-04
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells - Hematologic Malignancy
Phase 1 / Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology802024-12-312024-12-06
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology - Hematologic Malignancy, Haplo-identical Stem Cell Transplantation
Phase 1RecruitingUniversity Hospital, Geneva122024-11-262025-02-13
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
WBC100 QD - AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Phase 1RecruitingHangzhou Weben Pharma Co., Ltd362024-11-032026-10-16
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous) - Hematologic Malignancy, ALL, Childhood
Phase 1RecruitingSt. Jude Children's Research Hospital182024-10-162026-01-23
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
TGRX-1942 - Non Small Cell Lung Cancer, Advanced Solid Tumor
Phase 1RecruitingShenzhen TargetRx Co., Ltd.902024-07-082025-02-24
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
TRX103 - Hematologic Malignancy, GvHD
Phase 1RecruitingTr1X, Inc.362024-04-082025-04-15
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingShenzhen TargetRx Co., Ltd.302024-03-062024-04-10
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
autologous hematopoietic stem cells added to planned CAR T - Hematologic Malignancy, Large B-cell Lymphoma
Phase 1RecruitingJoshua Sasine, MD, PhD202024-03-022026-08-10
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1
Phase 1RecruitingKura Oncology, Inc.1712024-02-222026-08-20
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy
Phase 1 / Phase 2RecruitingUniversity Hospital Tuebingen602023-04-272025-04-27
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML
Phase 1RecruitingTherapeutic Advances in Childhood Leukemia Consortium542022-11-112024-12-06
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
Human T Lymphoid Progenitor (HTLP) injection - Hematologic Malignancy
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris102022-02-162026-08-12

Narrower conditions

Hematologic Neoplasms (18)  ·  Leukemia, Myeloid, Acute (6)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (6)  ·  Myelodysplastic Syndromes (3)  ·  Leukemia (2)  ·  Recurrence (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Graft vs Host Disease (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Lymphoma (1)

Broader conditions

Hematologic Diseases (18)  ·  Hemic and Lymphatic Diseases (18)  ·  Neoplasms (18)  ·  Neoplasms by Site (18)  ·  Neoplasms by Histologic Type (9)  ·  Leukemia (8)  ·  Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Leukemia, Lymphoid (6)  ·  Leukemia, Myeloid (6)  ·  Lymphatic Diseases (6)  ·  Lymphoproliferative Disorders (6)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Bone Marrow Diseases (3)

Interventions

fludarabine (7)  ·  Cyclophosphamide (5)  ·  Granulocyte Colony-Stimulating Factor (3)  ·  Mesna (3)  ·  Cytarabine (2)  ·  Filgrastim (2)  ·  Melphalan (2)  ·  Thiotepa (2)  ·  Antilymphocyte Serum (1)  ·  Azacitidine (1)  ·  Calcium Dobesilate (1)  ·  Decitabine (1)  ·  Dexamethasone (1)  ·  Hydrocortisone (1)  ·  Idarubicin (1)

Sponsors

St. Jude Children's Research Hospital (3)  ·  Shenzhen TargetRx Co., Ltd. (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Chinese PLA General Hospital (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hangzhou Weben Pharma Co., Ltd (1)  ·  Joshua Sasine, MD, PhD (1)  ·  Kura Oncology, Inc. (1)  ·  Ruijin Hospital (1)  ·  Therapeutic Advances in Childhood Leukemia Consortium (1)  ·  Tr1X, Inc. (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)  ·  University Hospital Tuebingen (1)  ·  University Hospital, Geneva (1)  ·  University of Alabama at Birmingham (1)

Countries

United States (9)  ·  China (6)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Swati Naik, MBBS (2)  ·  Adam Lamble, MD (1)  ·  Bo Jiang, MD (1)  ·  Brandon Triplett, MD (1)  ·  Jianxiang Wang, MD (1)  ·  Joshua Sasine, MD, PhD (1)  ·  Maria Grazia Roncarolo, MD (1)  ·  Mei Heng, M.D., Ph.D (1)  ·  Omer A Jamy, MD (1)  ·  Sayeef Mirza, MD (1)

Results publications

PMID 42495646

NIH funding

2019 (1)